диссертации / 120

91

131.Hozyasz KK, Mostowska A, Szaflarska-Poplawska A. et al. Polymorphic variants of genes involved in homocysteine metabolism in celiac disease.// Mol Biol Rep. 2012 Mar;39(3):3123-30.

132.Hurlock EC. 4th. Interferons: potential roles in affekt. Med Hypotheses. 2001 May, 56(5):558-66

133.Ikonomidis I et al. Low dose aspirin reduceselevated C-reactive protein plasma levels in patients with chronic stable angina by reducing cytokine plasma levels. Circulation 1998;98(1): 2562

134.Isordia-Salas I, Leaños-Miranda A, Sainz IM et al. Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients. Rev Esp Cardiol. 2009 Apr;62(4):365-72.

135.Jablonska E1, Puzewska W, Grabowska Z, VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer.// Cytokine. 2005 May 7;30(3):93-9.

136.Jankowska Е., Haehlong S., Czaтy А. et al. Activation of NFkВ system in peripheral blood leukocytes from patients with chronic heart failure Еuroр. J. Неаrt Faillure. 2005 ; 7: 984-990

137.Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011 Jul;217(1):227-33.

138.Jiang B1, Ryan KA, Hamedani A. et al. Prothrombin G20210A mutation is associated with young-onset stroke: the genetics of early-onset stroke study and meta-analysis. //Stroke. 2014 Apr;45(4):961-7.

139.Jick H, Miettinen OS. Regular aspirin use and myocardial infarction. Br Med J 1976 ; 1 : 1057–1058

140.Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities. Circ. 1996; 94:2057–2063.

92

141.K. Fragiadaki, K. Stamatelopoulos, A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis Volume 219, Issue 2, Pages 734–736, December 2011

142.Kaski J.C., Zouridakis E.G. Inflammation, infection and acute coronary plaque events. Eur Heart J. 2001;3(I):10-15.

143.Kasmeridis C, Apostolakis S, Lip GY. Aspirin and aspirin resistance in coronary artery disease.// Curr Opin Pharmacol. 2013 Apr;13(2):242-50.

144.Kathiresan S. Genetics of human cardiovascular disease // Cell. – 2012. – Mar 16. – № 148(6). – Р. 1242–57.

145.Kazemi MB, Eshraghian K, Omrani GR. et al. Homocysteine level and coronary artery disease.//Angiology. 2006 Jan-Feb;57(1):9-14.

146.Kim MA, Kim CJ, Seo JB, Chung WY, Kim SH, Zo JH, Rho EY, Shin S,

Yoon JH. The effect of aspirin on C-reactive protein in hypertensive

10.3109/10641963.2010.503302.

147.Klujber V, Lengyel B, Szabó T,et al. The plasma homocysteine, folic acid and vitamin B12 levels in young people with high risk for cardiovascular disease and its relation to metylentetrahydrofolate reductase (MTHFR) gene polymorphism. Orv Hetil. 2005 Apr 3;146(14):649-51. Hungarian.

148.Knowles JW, Wang H, Itakura H et al., Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. Am Heart J. 2007 Dec;154(6):1052-8.

149.Koenig W. Atherosclerosis involves more than just lipids: focus on inflammation. Eur Heart J. 1999;1(T):19-26.

150.Kohchi К, Takebayashi S, Hiroki T, Nobuyoshi M. Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. //Circulation. 1985; 71(4), 709-16

93

151.Koo HS, Lee HS, Hong YM. Methylenetetrahydrofolate reductase TT genotype as a predictor of cardiovascular risk in hypertensive adolescents.// Pediatr Cardiol. 2008 Jan;29(1):136-41. Epub 2007 Oct 5.

152.Kucharska-Newton A.M., Monda K.L., Campbell S. et al. Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study.// Atherosclerosis. 2011. V. 216. N. 1. P. 151–156.

153.Lane DA, Grant P.J Role of haemostatic gene polymorphisms in venous and arterial thrombotic disease // Blood. - 2000. - V. 95. - № 5. - P.1517-1532

154.Laraqui A, Allami A, Carrié A. Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. // Acta Cardiol. 2006 Feb;61(1):51-61.

155.Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338; 1245-1253.

156.Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. // Inflamm Res. - 2005; 54: pp. 395-411.

157.Levin R.I. et al. Aspirin inhibits vascular plasminogen activator activity in

vivo. J. Clin. Invest. 1984 ;74:571-580

158. Liang KW, Sheu WHH, Lee WL. Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand. // Can J Cardiol. - 2006; 22(8): pp. 691–696.

159.Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.

160.Libby P., Ridker P.M., Inflammation and atherosclerosis Circulation 2002; 105: 1135-1143

161.Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al; American Heart Association Strategic Planning Task Force and

94

Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s

Strategic Impact Goal through 2020 and beyond. Circulation. 2010;121: 586–613.

162.Lyson К., McCann S.M. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology 1991;54:262—6

163.Maat de M.P.M, Kastelein J.J.P., Jukema J.W. et al. - 455G/A polymorphism of the (J-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men // Arterioscler. Thromb. Vase. Biol. - 1998. - V. 18 -P. 265-271.

164.Machon В., Godson G. Lipoxins: endogenous regulators of inflammation. Am J Physiol. Renal Phisiol, 2004;286(2): 189-201

165.Mälarstig A, Eriksson P, Hamsten A, et al. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. //J. Heart. 2008 Jun;94(6):724-9.

166.Mallat Z., Bernarol S., Durier M. et al. Protective role of interleukin-10 in atherosclerosis. //Circ Res 1999;85:17-24.

167.Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M,

Christiaens T, Cifkova R, 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. //J Hypertens. 2013 Oct;31(10):192538.

168.Mannucci PM, Asselta R, Duga S. et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease.// J Thromb Haemost. 2010 Oct;8(10):2116-21.

169.Martiskainen M, Oksala N, Pohjasvaara T, Kaste M, Oksala A, Karhunen PJ, Erkinjuntti T. Beta-fibrinogen gene promoter A -455 allele associated with poor longterm survival among 55-71 years old Caucasian women in Finnish stroke cohort. BMC Neurol. 2014 Jun 22;14(1):137

95

170.Maseri A., Cianflone D. Inflammation in acute coronary syndromes. Eur Heart J. 2002;4(B):8-13.

171.Matarin M1, Brown WM, Hardy JA,et al. Association of integrin alpha2 gene variants with ischemic stroke.//J Cereb Blood Flow Metab. 2008 Jan;28(1):81-9

172.Matthys F, De Backer T, De Backer G, Stichele RV Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker? Eur J Prev Cardiol. 2014 Mar;21(3):354-65. doi: 10.1177/2047487312472077.

173.McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111–128, 1969.

174.Meguro S, Ishibashi M, Takei I., The significance of high sensitive C reactive protein as a risk factor for cardiovascular diseases. Rinsho Byori. 2012 Apr;60(4):356-61. [Article in Japanese].

175.Meinrad G. The evolving science of atherothrombotic disease. Eur H J 2008; 10(1):14-17

176.Melander О,Newton-Cheh Ch, Almgren P, et al. Novel and conventional biomarkers for the prediction of incident cardiovascular events in the community. JAMA. 2009 July 1; 302(1): 49–57.

177.Miller A.M. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011;8:22.[PubMed: 21871091]

178.Mitchell RS, Kumar V, Abbas AK, Fausto N Chapter 4 // Robbins Basic Pathology. — Eighth. — Philadelphia: Saunders, 2007. — ISBN 1-4160- 2973-7

179.Nemerovski CW, Salinitri FD, Morbitzer KA et al. Aspirin for primary prevention of cardiovascular disease events. Pharmacotherapy. 2012 Nov;32(11):1020-35.

180.Netea MG, Joosten LA, Lewis E et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12: 650– 56.

96

181.Nie Y, Gu H, Gong J, et al. Methylenetetrahydrofolate reductase C677T polymorphism and congenital heart disease: a meta-analysis. // Clin Chem Lab Med. 2011 Dec;49(12):2101-8.

182.Nikolopoulos GK1, Tsantes AE, Bagos PG et al. Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Thromb Res. 2007;119(4):501-10

183.Nisho E. Et al. Aspirin and salicylate enchances the induction of inducible nitric oxide synthase in cultured rat smooth muscle cells. Life Sci. 1998; 63:429-439

184.O’Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med. 2011; 365:2098–2109.

185.O’Donnell M, Xavier D, Liu L, Zhang H. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE Study): a case-control study Reference: Lancet 2010; 376:112-123.

186.O'Doherty MG, Jørgensen T, Borglykke A, Brenner H, Schöttker B, et al.

Repeated measures of body mass index and C-reactive protein in relation to all-cause mortality and cardiovascular disease: results from the consortium on health and ageing network of cohorts in Europe and the United States (CHANCES). Eur J Epidemiol. 2014 Nov 25. [Epub ahead of print]

187.Oliver MF. Cholesterol, coronaries, clofibrate and death.// N Engl J Med. 1978;299(24):1360-1362.

188.Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I. Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol. 2011 Dec 5;10:110. doi: 10.1186/1475-2840-10-110

189.Ossei-Geming N., Mansfield M.W., Stickland M.H. et al. Plasminogen activator inhibitor - 1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by

97

coronary angiography // Arterioscler. Thromb. Vase. Biol. -1997. - V. 17. -

P.33-37.

190.Ouyang S, Li Y, Liu Z, Chang H, Wu J. Association between MTR A2756G and MTRR A66G polymorphisms and maternal risk for neural tube defects: a meta-analysis.// Gene. 2013 Feb 25;515(2):308-12

191.Owen EP, Human L, Carolissen AA. et al. Hyperhomocysteinemia--a risk factor for abruptio placentae.// J Inherit Metab Dis. 1997 Jul;20(3):359-62.

192.Pastorelli L., Garg R.R., Hoang S.B., Spina L., Mattioli B., Scarpa M. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S

A.2010;107:8017–8022.[PubMed: 20385815]

193.Patel A., ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide onmacrovascular andmicrovascular outcomes in patients with type 2 diabetesmellitus (the ADVANCE trial): a randomized controlled trial. // Lancet 2007.–370.–829-840.

194.Patti G, Fossati C, Nusca A et al. Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis. // J Thromb Thrombolysis. 2009 May;27(4):413-20.

195.Pegoraro RJ, Ranjith N. Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction. Cardiovasc J S Afr. 2005 Sep- Oct;16(5):266-70.

196.Peto R, Gray R, Collins R et al. Randomized trial of prophylactic daily aspirin in British male doctors. – Br Med J 1988 – 296 – p. 313–6

197.Pindersky Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. //Atheroscler ThrombVasc Biol 1999;19:2847-53.

98

198.Pinotti M., Toso R., Girelli D. et al. Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies.// Blood. 2000. V. 95. P. 3423–3428.

199.Poort S.R., Rosendaal F.R., Reitsma P.H. et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. //Blood. 1996. V. 88. P. 3698–3703.

200.Prefontaine D., Lajoie-Kadoch S., Foley S., Audusseau S., Olivenstein R., Halayko A.J. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183:5094– 5103.[PubMed: 19801525]

201.Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.//Ann Intern Med. 1997 Nov 15;127(10):895-903.

202.PROGRESS CollaborativeGroup. Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack.//Lancet 2001. –358. –1033-41.

203.Protogerou A.D., Zampeli E., Reiner AP, Carty CL, Carlson CS et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost. 2006 Jun;4(6):1279-87.

205.Reiner AP1, Carty CL, Carlson CS, et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. // J Thromb Haemost. 2006 Jun;4(6):1279-87.

206.Ridker P, Cook N, Min Lee L et. al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. – N Engl J Med 2005: 352

99

207.Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297:611–619.

208.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. //N Engl J Med. 2008;359(21):2195-2207.

209.Robbins M., Topol E.J. Inflammation in acute coronary syndromes. Acute coronary syndromes / E.J. Topol. ? 2nd ed., revised and expanded. N.Y.: Marcel Dekker Inc., 2001. P.1-31.

210.Román GC. Vascular dementia prevention: a risk factor analysis.//

Cerebrovasc Dis. 2005;20 Suppl 2:91-100. Epub 2005 Dec 2.

211.Rongioletti M, Baldassini M, Papa F. et al. Homocysteinemia is inversely correlated with platelet count and directly correlated with sEand sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase.// Platelets. 2005 May-Jun;16(3-4):185-90.

212.Rosendaal F.R., Siscovick D.S., Schwartz S.M. et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. // Blood. 1997. V. 90. P. 1747–1750.

213.Ross R. Atherosclerosis: an inflammatory disease N Engl J Med 1999;340: 115-126

214.Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S.C., Dinarello C.A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40—7

215.Schumman R.R. Zweigner G.M. A novel acute-phase marker: lipopolysaccharide binding protein (LBP) Clin. Chem. Lab. Med. 1999; 37(3): 271-274

216.Sehestedt T., Jeppesen J., Hansen T.W. et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. // Eur. Heart J. – 2010 – 31. – p.883–891.

100

217.Sehestedt T., Jeppesen J., Hansen T.W. et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. // J. Hypertens. – 2012. – 30. – p.1928–1936.

218.Selak V, Elley CR, Wells S et al. Aspirin for primary prevention: yes or no? J Prim Health Care. 2010 Jun;2(2):92-9.

219.Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower- than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.// Lancet. 2003;361(9364):1149-1158.

220.Shafey M, Anderson JL, Scarvelis D. et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis.// Thromb Haemost. 2007 Apr;97(4):635-41.

221.Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. //N Engl J Med. 1995;333(20):13011307.

222.Simioni P., Prandoni P., Burlina A., et al. Hyperhomocysteinemia and deepvein thrombosis. A case control study.// 1996. - V. 76. - P. 883-886.

223.Siscovick D.S. Schwarz S.M. Chlamidia pneumonia, Herpes simplex virus type 1 and Cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults. The cardiovascular health study. Circulation 2000; 102:2335-2340;

224.Stegnar M., Uhrin P., Peemel P. et al. The 4G/5G sequence polymorphism in promoter of plasminogen activator inhibitor - 1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism // Thromb. Haemost. - 1998. - V.79. - P 975-979.